Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults With Thrombocytopenia Associated With Liver Disease Prior to an Elective Procedure

Next Previous
X
Search
Trial Profile

A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults With Thrombocytopenia Associated With Liver Disease Prior to an Elective Procedure

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avatrombopag (Primary)
  • Indications Thrombocytopenia
  • Focus Registrational; Therapeutic Use
  • Acronyms ADAPT II
  • Sponsors Dova Pharmaceuticals; Eisai Inc

    • Most Recent Events

    • 30 Apr 2020 According to a Dova Pharmaceuticals media release, DOPTELET (avatrombopag) has been granted approval from the China National Medical Products Administration (NMPA) for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure (i.e., the CLD indication).The approval was based on safety and efficacy data from two global Phase 3, double-blind, placebo-controlled trials (NCT01972529 and NCT01976104).
    • 27 Jun 2019 According to an Dova Pharmaceuticals media release, the company will host a conference call to discuss the approval by FDA.
    • 27 Jun 2019 According to an Dova Pharmaceuticals media release, the U.S. Food and Drug Administration(FDA) has approved a supplemental New Drug Application(sNDA) that expands the use of DOPTELET(avatrombopag) to include the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top